Biogen

We’re pleased to share that Biogen received a positive CHMP opinion from the European Medicines Agency (EMA) for a proposed rheumatoid arthritis biosimilar, based on a robust analytical, non-clinical and clinical data package comparing the product to the reference biologic. Read more in the news release: https://ow.ly/wmu650RosWo

We had a great time recognizing Bring Your Child to Work Day at our Cambridge headquarters! Thank you to our wonderful colleagues for sharing a part of your family with us.    #TeamBiogen 

Read our Q1 2024 financial results here: https://ow.ly/CIRu50RmFk3 #Earnings

We are traveling to the Alzheimer’s Disease International (ADI) Global Conference 2024 in Krakow, Poland, which is kicking off tomorrow. We look forward to connecting with diverse members of the AD community to discuss this global health priority and innovative research as we look to the future. We hope to see you there!    #Alzheimers | #ADI2024 

Strengthening innovation in rare disease and increasing access to treatments in the EU is key to transforming patient care. If you have missed our Biogen & POLITICO Live event on April 12th, you can now watch it here: https://bit.ly/4b1OGeH   #RareDiseases |#access |#patients #health |#policy |#EUpolicy 

Laboratories are resource intensive and typically consume 4x more water and 10x more energy than offices do, according to My Green Lab. That’s why we’re proud that 100% of our labs have been certified through My Green Lab, the first large biotech to reach this milestone. More than 700 global employees were involved to identify ways to make our labs more sustainable.  #EarthDay | #EarthMonth | #MyGreenLab 

Don't miss out on today's session (5) at 20th Biosimilar Medicines Conference, starting today at 9:25am CET! Biogen's Head of Biosimilars Market Access, Magnus Bodin, will be a speaker at a panel session. It's a great opportunity to engage in crucial discussions that will shape the future of #MarketAccess for biosimilars. See you there!   #Biogen #Biosimilars #BIOS24 #MarketAccess

The 20th Biosimilar Medicines Conference starts tomorrow! Join us during session 5 focusing on Reforming EU and National Market Policies. It’s a great chance to learn about the national market dynamics that profoundly influence biosimilar competition and the sustainable adoption of biological medicines. Learn More about the Conference: https://lnkd.in/dTHqtHU2 #Biogen |#Biosimilars |#BIOS24 |#MarketAccess

Our commitment to addressing health disparities in multiple sclerosis research is driven by our mission to enhance the lives of the patients we serve. At the American Academy of Neurology Annual Meeting in Denver, we are presenting work that highlights our leadership and progress on this front, including our real-world fumarate study that represents the largest number of Black and Hispanic patients with MS to be included in a study of this kind. Join us virtually or in Denver to learn more: https://ow.ly/nmAg50Reqkl #HealthEquity | #Biogen | #AANAM

We look forward to joining the 2024 American Academy of Neurology (AAN) Annual Meeting to share more about our latest research in multiple sclerosis and Friedreich ataxia, as well as discuss the future of innovation in Alzheimer’s disease. Join us virtually or in Denver to learn more and attend our upcoming poster presentations. View the program: https://ow.ly/n1bX50RekVa #Biogen | #AANAM | #Neuroscience